BETA: Please send your feedback!
Gencurix
229000-KR:KON
Medical Specialties
—
MICRO cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
About
Medical Specialties
Founded 2011
Gencurix, Inc. is engaged in developing and manufacturing cancer diagnostic test kits. Its products include GenesWell BCT, GenesWell ddEGFR Mutation Test, GenesWell CDx EGFR Mutation Test, and GenesWell ddEGFR Mutation Test. The company was founded on September 21, 2011 and is headquartered at Seoul, South Korea.
website
Headquarters
Executives
Name | Title | Gender |
Sang-Rae Cho | Chief Executive Officer & Director | Male |
Young-Ho Moon, PhD | Chief Technology Officer, Director & VP | Male |
Mindful Investing Summary
Gencurix - Competitors and Related Companies
How Gencurix stacks up to its peers in the Medical Specialties industry or with competing business segments.
Gencurix
229000-KR:KON
Medical Specialties
—
MICRO cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
Loading…